13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q4 2025 · Filed February 12, 2026 · Accession 0001193125-26-048719
Total Value
$151.1M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | GLUE | 4,382,687 | $68.7M | 45.49% |
| 2 | Lenz Therapeutics, Inc. | LENZ | 2,656,888 | $42.5M | 28.14% |
| 3 | Jade Biosciences, Inc. | JBIO | 1,525,820 | $23.5M | 15.59% |
| 4 | CRISPR Therapeutics AG | CRSP | 148,831 | $7.8M | 5.17% |
| 5 | Contineum Therapeutics, Inc. | CTNM | 542,628 | $6.2M | 4.11% |
| 6 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $1.5M | 1.00% |
| 7 | Tempest Therapeutics, Inc. | TPST | 269,772 | $774,246 | 0.51% |